EU H2020 Project "C-STEMGMP (c-GMP compliance of C-stem, an IPSc based cell therapies production..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/226324/index.html

C-stemGMP project word cloud

Explore the words cloud of the C-stemGMP project. It provides you a very rough idea of what is the project "C-stemGMP" about.

tissues scalable mass provides failing critical gmp standard material tft models regenerative healthcare alliance manufacturing pme pharmas secure industry programs 24 vision certified big bottleneck market therapies killing incurable patients materials therapy chronic consolidate human therapeutics medicine pluripotent position diseases suffering volume degenerative regulatory cellular 2bn strategy treefrog time 2018 boomed economic encapsulates encapsulation relations players treatments cells approve financial industrial stemtm laquo clients gene underway safety affordable capacity rare replace instrument 2012 baseline stem standards clinical global benefits compliant supplier viability agencies pharmaceutical 028 2025 device outpace scaling cell raw trials culture practices months quality meet settings outstanding good fda capture multiplication anticipates raquo invested

Project "C-stemGMP" data sheet

The following table provides information about the project.

Coordinator	TREEFROG THERAPEUTICS Organization address address: 146 RUE LEO SAIGNAR BATIMENT city: BORDEAUX postcode: 33000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	3˙382˙855 €
EC max contribution	2˙367˙998 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2019
Duration (year-month-day)	from 2019-11-01 to 2021-10-31

#	participants	country	role	EC contrib. [€]
1	TREEFROG THERAPEUTICS	FR (BORDEAUX)	coordinator	2˙367˙998.00

TREEFROG THERAPEUTICS

FR (BORDEAUX)

coordinator

2˙367˙998.00

Project objective

Scaling-up cell therapy manufacturing provides many benefits: the capacity to replace failing tissues in patients suffering from incurable chronic or degenerative diseases, affordable treatments and the economic viability of the development of cell therapies for rare diseases. The baseline of TreeFrog Therapeutics (TFT), “Cell Therapy for All”, encapsulates this vision.TFT has already obtained outstanding results with its C-StemTM stem cell culture technology, fully scalable and allowing a high cell multiplication factor. The cell therapy market has boomed since 2012. In 2018, 1,028 clinical trials were underway according to the Alliance for Regenerative Medicine and big pharmas invested €6.2bn in cell therapy programs. The FDA anticipates to approve « 10 to 20 cell and gene therapy products a year » by 2025. A critical bottleneck remains for the cell therapies that will reach the market within 5 to 10 years: the industrial production of human induced pluripotent stem cells, the raw material for cell therapies. Current manufacturing models do not meet the standards of regulatory authorities and healthcare systems in terms of safety, cost, volume and lead time. With C-StemTM, TFT is in the best position to become the global supplier of stem cells for cell therapy’s industry. Tailored for cost-killing mass-production of stem cells, while defining a new quality standard for cellular products, C-StemTM needs to be certified for “Good Manufacturing Practices” (GMP) to be used in clinical settings and capture its market. This project requires, within 24 months, to develop a GMP encapsulation device, to replace non-compliant materials, while developing relations with EU/US regulatory agencies and clients from the pharmaceutical industry. TFT has a “go-global” strategy and aims at leading its market within 7 years. Funding from the H2020 Instrument PME Phase 2 would secure the project and consolidate TFT on the financial level, a key element to outpace non-european players.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "C-STEMGMP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "C-STEMGMP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)